Therapeutic device kit
The therapeutic device kit directly administers an anticancer drug to tumors, inducing immunogenic cell death and activating anti-tumor immunity, addressing the limitations of intravenous delivery and enhancing treatment efficacy.
Patent Information
- Application Number
- JP2021156771
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2021-09-27
- Publication Date
- 2024-11-13
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing cancer treatments, such as intravenous administration of anticancer drugs, face challenges in delivering effective doses to tumors while minimizing systemic side effects, and there is a need for methods that enhance antitumor immunity.
A therapeutic device kit comprising an anticancer drug that causes immunogenic cell death and an administration device capable of directly delivering the drug to tumor tissue, inducing activation of anti-tumor immunity.
The kit achieves higher antitumor effects by directly targeting tumor tissue with the anticancer drug, enhancing immune response and reducing systemic side effects.
Smart Images

Figure 2024160189000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a therapeutic device kit. [Background technology]
[0002] Intravenous administration is the standard method for administering anticancer drugs used in chemotherapy for cancer treatment. However, intravenous administration of anticancer drugs has problems such as a small amount of drug that can reach the tumor, which can reduce the therapeutic effect, and systemic side effects.
[0003] Meanwhile, cancer immunotherapy, which applies the immune system to treat diseases, has been attracting attention. The functions of the immune system are generally expressed through two mechanisms: humoral immunity and cellular immunity. Cellular immunity has the ability to kill and eliminate cancer cells, and it has been found to play an important role in cancer immunotherapy. Among the cells that make up cellular immunity, cytotoxic T cells (hereinafter simply referred to as CTLs) are primarily responsible for killing cancer cells.
[0004] The induction of CTLs is usually expressed as follows: Endogenous antigens, such as proteins produced by virus-infected cells or cancer cells, are ubiquitinated and then degraded into peptides by the proteasome. The degraded peptides bind to major histocompatibility complex (MHC) class I molecules, and the resulting complexes are presented to CD8-positive T cells on the surface of antigen-presenting cells, activating the CD8-positive T cells. The activated CD8-positive T cells then differentiate into CTLs. The induction of CTLs is a necessary factor for effective cancer immunotherapy.
[0005] For example, Patent Document 1 discloses MHC class II ligands or MHC class II-like ligands as adjuvants for vaccines to enhance antigen-specific immune responses.
[0006] On the other hand, cancer immunotherapy that combines two drugs is also being studied, in the hope of enhancing the antitumor effect of the combination of drugs by utilizing different immune systems. For example, Patent Document 2 discloses a drug for treating tumors that combines an immunotoxin containing a single-chain variable domain antibody fused to a PE38-truncated Pseudomonas exotoxin with an immune checkpoint inhibitor. [Prior art documents] [Patent documents]
[0007] [Patent Document 1] Special Publication No. 2001-510806 [Patent Document 2] Special Publication No. 2018-533626 Summary of the Invention [Problem to be solved by the invention]
[0008] As described above, there is a need for methods that can efficiently induce / activate anti-tumor immunity and have a more effective anti-tumor effect.
[0009] Therefore, an object of the present invention is to provide a method having a stronger antitumor effect. [Means for solving the problem]
[0010] The present invention is a therapeutic device kit having an anticancer agent that induces immunogenic cell death and an administration device capable of administering the anticancer agent directly to tumor tissue, wherein the anticancer agent is administered using the administration device to induce activation of anti-tumor immunity. Effect of the Invention
[0011] According to the present invention, it is possible to provide a therapeutic device kit having a stronger antitumor effect. [Brief description of the drawings]
[0012] [Figure 1] 1 is a graph showing the tumor volume of each group in the drug efficacy evaluation in mice. [Diagram 2] FIG. 1 shows the survival curves of each group in the drug efficacy evaluation in mice. [Diagram 3] FIG. 1 shows a gating flow chart for flow cytometry. [Figure 4] 1 is a graph showing the total CTL number in each group in the evaluation of CTL activation (mouse) using flow cytometry.
[0013] [Diagram 5] 1 is a graph showing the number of AH-1 specific CTLs in each group in the evaluation of CTL activation (mouse) using flow cytometry. [Figure 6] Fig. 13 is a graph showing the number of CD69+ CTLs in each group in the evaluation of CTL activation (mouse) using flow cytometry. [Figure 7] FIG. 1 is a diagram showing a treatment device kit including an administration device used in a first embodiment of a method for administering an anticancer agent. [Figure 8] FIG. 2 shows the tip of an injection needle. [Figure 9] FIG. 2 shows the tip of an injection needle. [Figure 10] FIG. 2 is a diagram showing the configuration of an outer cylinder that constitutes the administration device. [Figure 11] FIG. 2 is a diagram showing the configuration of an outer cylinder that constitutes the administration device. [Figure 12] 13A and 13B are diagrams showing auxiliary tools constituting the treatment device kit. [Figure 13] 13A and 13B are diagrams showing auxiliary tools constituting the treatment device kit. [Figure 14] 11 is a schematic diagram showing an endoscope, an administration device, etc. used in a second embodiment of the anticancer agent administration method. FIG. [Figure 15] FIG. 15 is a diagram showing the tip portion of the endoscope shown in FIG. [Figure 16]FIG. 15 is a diagram showing a state in which an anticancer agent is administered to an affected area using the endoscope shown in FIG. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] Hereinafter, embodiments of the present invention will be described. Note that the present invention is not limited to the following embodiments.
[0015] In this specification, the range "X to Y" includes X and Y and means "X or more and Y or less." Furthermore, in this specification, unless otherwise specified, operations and measurements of physical properties are performed under the conditions of room temperature (20°C or more and 25°C or less) and relative humidity of 40% RH or more and 50% RH or less.
[0016] One aspect of the present invention is a therapeutic device kit having an anticancer agent that induces immunogenic cell death and an administration device capable of administering the anticancer agent directly to tumor tissue, wherein the anticancer agent is administered using the administration device to induce activation of anti-tumor immunity.
[0017] Each component will be described below.
[0018] [Anti-cancer drugs that induce immunogenic cell death] "Immunogenic cell death" refers to a form of cell death that is easily recognized as non-self by immune cells, usually accompanied by the expression or release of DAMPs such as calreticulin, ATP, and HMGB1.
[0019] The anticancer drug that induces immunogenic cell death (hereinafter, also simply referred to as anticancer drug) is preferably at least one selected from the group consisting of doxorubicin, epirubicin, oxaliplatin, paclitaxel, and pharma- ceutical acceptable salts thereof, and more preferably doxorubicin and / or its pharma-ceutical acceptable salts. That is, a preferred embodiment of the present invention is a therapeutic device kit having doxorubicin and / or its pharma-ceutical acceptable salts, and an administration device capable of administering doxorubicin and / or its pharma-ceutical acceptable salts directly to tumor tissue. An example of the doxorubicin salt is doxorubicin hydrochloride.
[0020] The above pharma- ceutically acceptable salts include salts at basic groups such as amino groups, and acidic groups such as hydroxyl groups and carboxyl groups.
[0021] Examples of salts of basic groups include salts with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, boric acid, nitric acid and sulfuric acid; salts with organic carboxylic acids such as formic acid, acetic acid, lactic acid, citric acid, oxalic acid, fumaric acid, maleic acid, succinic acid, malic acid, tartaric acid, aspartic acid, trichloroacetic acid and trifluoroacetic acid; and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid.
[0022] Salts of acidic groups include, for example, salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts; and salts with nitrogen-containing organic bases such as trimethylamine, triethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-ephenamine, and N,N'-dibenzylethylenediamine.
[0023] The anti-cancer drug induces the activation of anti-tumor immunity by, for example, administering it using an administration device described later. The induction of the activation of anti-tumor immunity can also be controlled, for example, by the dosage of the anti-cancer drug. Here, "activation of anti-tumor immunity" specifically refers to an increase in the number of cytotoxic T cells (CTL) of 150% or more, preferably 170% or more, and more preferably 200% or more, compared to a control in which no anti-cancer drug is administered. The number of cytotoxic T cells (CTL) can be measured by the method for measuring the total CTL number described in the Examples below.
[0024] The dosage of the anticancer agent is appropriately determined for each individual case, taking into consideration the symptoms, age, sex, etc. of the patient. According to the therapeutic device kit of this embodiment, the anticancer agent that induces immunogenic cell death can activate antitumor immunity. Therefore, it is expected that the dosage can be reduced compared to the dosage of a normal anticancer agent. The dosage of the anticancer agent in humans is, for example, 0.1 mg / Kg / Day or less, and may be 0.01 to 0.1 mg / Kg / Day, or may be 0.020 to 0.070 mg / Kg / Day. In the case of systemic administration, the anticancer agent, for example, doxorubicin hydrochloride, usually requires an administration of 0.20 mg / Kg or more. In addition, the dosage of the anticancer agent per tumor volume is, for example, 100 mm of tumor tissue. 3 The amount is 6 μg or more, and may be 60 μg or less, or may be 20 μg or less.
[0025] The number of times the anticancer agent is administered per course is not particularly limited, and may be a single administration or multiple administrations, for example, 1 to 3 administrations per course. The anticancer agent may be repeatedly administered at intervals of about 1 to 4 weeks. Furthermore, when there are multiple tumors, the anticancer agent may be administered to the multiple tumors.
[0026] The anticancer agent may constitute a composition together with pharma- ceutically acceptable additives depending on the desired product form.
[0027] "Pharmaceutically acceptable" is used to refer to compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications, commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment.
[0028] Pharmaceutically acceptable additives may include solvents (e.g., physiological saline, water for injection, buffer solution, etc.), membrane stabilizers (e.g., cholesterol, etc.), isotonicity agents (e.g., sodium chloride, glucose, glycerin, etc.), antioxidants (e.g., tocopherol, ascorbic acid, glutathione, etc.), preservatives (e.g., chlorbutanol, parabens, etc.). Physiological saline refers to an inorganic salt solution adjusted to be isotonic with the human body, and may further have a buffer function. Physiological saline includes saline containing 0.9 w / v% (weight / volume percent) sodium chloride, PBS, Tris-buffered saline, etc.
[0029] [Administration device] The administration device is not particularly limited in terms of its specific configuration as long as it can directly administer an anticancer drug to tumor tissue, but two administration devices will be described below as examples.
[0030] (First embodiment of anticancer drug administration device) Fig. 7 is a schematic diagram showing a treatment device kit 1 including an administration device 100. The treatment device kit 1, as generally described with reference to Fig. 7, includes a medical device 200, an administration device 100, an instrument 300, and an auxiliary tool 400. The details will be described below.
[0031] (Medical Devices) As shown in FIG. 7, the medical device 200 includes a cylindrical portion 210, a pressing portion 220, a sealing member 230, and a connecting member 240.
[0032] The tube portion 210 has a semi-closed space for accommodating an anticancer drug. The tube portion 210 is configured in a tubular shape such as a cylinder, and has openings at both ends in the axial direction of the tube. A pressing portion 220 can be movably disposed in one opening (also called a base end opening). A connecting member 240 can be attached to the other opening (also called a tip end opening).
[0033] The pressing portion 220 includes a pusher that can increase or decrease the size of the semi-closed space of the tube portion 210. The pusher of the pressing portion 220 is configured so that a tip side is accommodated in the semi-closed space of the tube portion 210 and a base end side is disposed outside the tube portion 210. The pusher of the pressing portion 220 is configured to change the size of the semi-closed space in which a drug (anticancer drug, hereinafter also referred to as drug) is accommodated by moving relative to the tube portion 210 in the axial direction of the tube portion 210.
[0034] The size of the semi-closed space of the tube part 210 is reduced by the pusher of the pressing part 220, and the medicine contained in the semi-closed space flows into the lumen of the injection needle 120 and can be administered to the patient. The pusher of the pressing part 220 may be operated manually by the surgeon holding it with the fingers or the like, or the pusher may be operated by appropriately combining mechanical elements such as a motor and gears.
[0035] The seal member 230 is configured to be attached to the tip portion in the axial direction of the plunger of the pressing portion 220. The seal member 230 slidably engages with the inner wall of the cylindrical portion 210 to prevent the drug contained in the semi-closed space of the cylindrical portion 210 from circulating from anywhere other than the injection needle 120.
[0036] The connecting member 240 is attached to an opening at the tip side of the cylindrical portion 210. The connecting member 240 is configured to be hollow so that a drug can flow inside. The connecting member 240 is attached to the tip portion of the cylindrical portion 210, and the inner cavity of the connecting member 240 is configured to communicate with the semi-closed space of the cylindrical portion 210.
[0037] (Administration Device) As shown in FIG. 7 etc., the administration device 100 includes an inner cylinder 110, an injection needle 120, an outer cylinder 130, a detection unit 140, a notification unit 150, and a control unit (not shown).
[0038] The inner cylinder 110 is connected to the medical device 200, and has therein a liquid transfer path for the anticancer drug that flows from the medical device 200 together with the injection needle 120. In this embodiment, the inner cylinder 110 has a connection part 111 with the medical device 200 provided radially outward on the cylindrical side surface. In addition, a detection part 140, which will be described later, is provided on the route of the liquid transfer path provided inside the inner cylinder 110.
[0039] The injection needle 120 is configured to be able to directly administer an anticancer agent to tumor tissue of a living body. The injection needle 120 includes a hollow member with a small diameter, and is configured to have a liquid feed path inside the hollow member that communicates with the liquid feed path of the inner cylinder 110, and a tip opening that communicates with the liquid feed path at the tip. The dimensions of the injection needle 120 are appropriately selected depending on the administration target and the tumor location so that the injection needle 120 can be punctured from the body surface to the tumor present inside the body. When the target is a human, the longitudinal dimension can be configured to be 150 mm or more so that the injection needle 120 can be punctured from the body surface to the tumor present inside the body. The dimensions of the injection needle 120 may be, for example, 50 to 300 mm.
[0040] FIG. 8 is a diagram showing an opening in the injection needle 120 for discharging a drug, and FIG. 9 is a diagram showing an opening in an injection needle 120a according to a modified example of the injection needle 120 for discharging a drug. In the injection needle 120, the opening for discharging an anticancer drug is provided so as to face the tip side in the longitudinal direction in this embodiment as shown in FIG. 8. However, the opening of the injection needle is not limited to this, and other than the above, as shown in the injection needle 120a in FIG. 9, a part facing the tip side near the tip in the longitudinal direction may be solid, and an opening for discharging a drug from near the tip outward in the radial direction may be provided in a plurality of openings in the circumferential direction. In a form in which there is an opening in the radial direction, the tip may be sharp. In one aspect of the present invention, the administration device has a drug solution discharge hole at the tip or side of the injection needle.
[0041] Furthermore, the injection needle 120 can perform an operation (priming) of flowing the anticancer drug to the tip of the liquid feed path of the injection needle 120 while using an auxiliary tool 400 described later. The auxiliary tool 400 will be described later. In another aspect of the present invention, the administration device includes a mechanism for safely filling the injection needle with the anticancer drug.
[0042] The outer cylinder 130 comprises a base portion 131 capable of storing at least a part of the inner cylinder 110, and a tip portion 132 capable of storing the tip portion of the injection needle 120. Figures 10 and 11 are views showing the base portion 131 and the tip portion 132 of the outer cylinder 130. In this embodiment, the base portion 131 and the tip portion 132 are formed so as to be continuous in the longitudinal direction of the injection needle 120. The base portion 131 and the tip portion 132 are distinguished by a two-dot chain line L1 shown in Figure 10, and the base portion 131 and the tip portion 132 may each be referred to as an "outer cylinder".
[0043] The detection unit 140 is configured to be provided in a liquid transfer path provided inside the inner cylinder 110. The detection unit 140 includes a sensor capable of measuring the injection pressure when an anticancer drug is administered to an affected area by the injection needle 120. The sensor of the detection unit 140 is not particularly limited as long as it can measure the pressure of the anticancer drug flowing through the liquid transfer path, and one example is a diaphragm-type sensor.
[0044] The notification unit 150 is configured to be capable of notifying the pressure during injection of the anticancer drug measured by the sensor of the detection unit 140. The notification unit 150 is configured to be capable of being electrically connected to the detection unit 140 by wiring or the like that is led from the sensor of the detection unit 140 through the base end side of the inner tube 110 to the outside of the inner tube 110.
[0045] The specific configuration of the notification unit 150 is not particularly limited as long as it can notify the user of the pressure value detected by the sensor associated with the detection unit 140. As an example, the notification unit 150 can include an LCD display or an organic EL display that displays the pressure value visually using numbers, graphs, etc.
[0046] The control unit is provided to control electrically connected components such as the detection unit 140 and the notification unit 150 in the administration device 100. The control unit is configured to include a processor such as a CPU or a GPU, a main memory such as a RAM, and an auxiliary memory such as a ROM, an HDD, or an SSD. The control unit can be housed inside the housing of the notification unit 150.
[0047] (Instruments) The device 300 is configured so that, when connected to the assisting tool 400, the user operates the device 300 to create a negative pressure in the first semi-closed space 413 of the tubular part 410 of the assisting tool 400 (FIGS. 12 and 13). The device 300 includes the tubular part 310, a pressing member 320, a sealing member 330, and a connecting member 340, as shown in FIG.
[0048] The cylindrical portion 310 is similar to the cylindrical portion 210 of the medical device 200, the pressing member 320 is similar to the pressing member 220, and the sealing member 330 is similar to the sealing member 230, so detailed descriptions thereof will be omitted.
[0049] The connecting member 340 is configured to include a hollow member such as a tube through which a fluid such as gas can flow. The surgeon attaches one end of the connecting member 340 to the tube portion 310 and the other end to the connection portion 440 of the auxiliary tool 400, and performs an operation to move the pressing member 320 so as to increase the semi-closed space of the tube portion 310. This makes it possible to create a negative pressure in the first semi-closed space 413 of the tube portion 410 in the auxiliary tool 400.
[0050] In this embodiment, the instrument 300 is configured to have components similar to those of the medical device 200, but the specific configuration is not limited to that of the medical device 200 as long as the first semi-closed space 413 of the auxiliary tool 400 can be made negative pressure.
[0051] (Assistive devices) 12 and 13 are diagrams for explaining the auxiliary tool 400. The auxiliary tool 400 prevents the anticancer drug from leaking out from the tip of the injection needle 120 during priming to circulate the anticancer drug through the liquid transfer path of the injection needle 120, which may result in the anticancer drug being scattered onto medical staff or patients. As shown in FIG. 12 etc., the auxiliary tool 400 includes a tubular portion 410. The tubular portion 410 of the auxiliary tool 400 includes a stopper 420, a valve member 430, and a connection portion 440.
[0052] The tubular portion 410 is provided with a first semi-closed space 413 and a second semi-closed space 414 that form an internal space so as to surround the tip of the hollow injection needle 120 through which the anticancer drug can flow. The tubular portion 410 is configured in a tubular shape such as a cylinder in which the first semi-closed space 413 and the second semi-closed space 414 are provided. However, the specific shape of the tubular portion 410 is not limited to a cylinder, and it may be configured as a square tube (polygonal prism) other than a cylinder, etc., as long as it is possible to prevent the drug from leaking to the outside during priming.
[0053] The cylindrical portion 410 has openings on both the tip side and base side in the axial direction of the cylindrical shape, which communicate the first semi-closed space 413 or the second semi-closed space 414 with the outside. In this specification, the tip side opening that communicates the first semi-closed space 413 with the outside is called the first opening 411, and the base side opening that communicates the second semi-closed space 414 with the outside is called the second opening 412. The dimension of the first semi-closed space 413 in the insertion direction of the injection needle 120 in FIG. 12 (vertical dimension d1) can be configured to such an extent that the injection needle 120 does not contact or is difficult to reach the wall portion 415 facing the injection needle 120 when inserted. In addition, by configuring the cylindrical portion 410 from a transparent material, it is possible to visually confirm that the anticancer drug is scattered from the injection needle 120 in the first semi-closed space 413 during priming, and to confirm the completion of priming.
[0054] In this embodiment, the stopper 420 is provided in the second semi-closed space 414, which is the internal space of the tube portion 410. The stopper 420 is configured to have a third opening 421 through which the injection needle 120 of the administration device 100 is inserted and which prevents the insertion of needles other than the injection needle 120.
[0055] The third opening 421 is configured so that the area of a cross section intersecting the axial direction becomes smaller as the axial direction progresses from the direction of entry into the first semi-closed space 413 of the cylindrical portion 410. Such a configuration makes it easier to insert the injection needle 120 into the third opening 421. In this embodiment, the third opening 421 is configured to have a stepped shape in which the radial dimension changes stepwise. However, the third opening may be configured to have a tapered shape instead of or in addition to the stepped shape.
[0056] The valve member 430 is provided adjacent to the second opening 412 in the axial direction of the internal space of the cylindrical portion 410. The internal space of the cylindrical portion 410 can be divided by the valve member 430 into a first semi-closed space 413 on the first opening 411 side and a second semi-closed space 414 on the second opening 412 side.
[0057] The valve member 430 can be made of the same elastic material as the elastically deformable elastic material constituting the seal member 230 of the medical device 200. The valve member 430 has a substantially circular cross-sectional shape similar to the cross-sectional shape intersecting the axial direction of the cylindrical portion 410. The valve member 430 is provided adjacent to the stopper 420 in this embodiment.
[0058] In this embodiment, the valve member 430 is configured to have a notch 431 provided in approximately the center as shown in Fig. 12 etc. This allows the tip of the injection needle 120 to pass through the valve member 430 from the notch 431 and advance (insert) into the first semi-closed space 413 of the tubular part 410 by elastically deforming the valve member 430 from the second opening 412 of the tubular part 410 as shown in Fig. 13.
[0059] The valve member 430 holds the injection needle 120 with the tip of the injection needle 120 inserted into the first semi-closed space 413. The valve member 430 prevents leakage of the anticancer drug from the side of the second opening 412 in the internal space with the injection needle 120 inserted therethrough.
[0060] In this embodiment, the notch 431 of the valve member 430 is formed in a cross shape. However, the specific shape of the notch is not limited to a cross, as long as the injection needle 120 can be inserted into the valve member and the anticancer drug does not flow out from the insertion point when inserted. In addition, as long as the tip of the injection needle 120 can be inserted into the first semi-closed space 413 while the injection needle 120 is in close contact with the valve member, the valve member does not need to have a notch.
[0061] The connecting part 440 is provided on the first opening 411 side in the axial direction of the cylindrical part 410. The connecting part 440 is configured to be connectable to an instrument 300 that creates a negative pressure in the first semi-closed space 413 (internal space) of the cylindrical part 410, as described below.
[0062] The connection part 440 is provided with a first opening 411, and the first opening 411 is configured to communicate with the first semi-closed space 413 of the tubular part 410. With this, by operating the instrument 300 with the connection member 340 or the like of the instrument 300 attached to the connection part 440, the first semi-closed space 413 of the tubular part 410 can be made to have a negative pressure.
[0063] In this embodiment, the connecting part 440 is configured in a hollow cylindrical shape with an axis parallel to the insertion direction of the injection needle 120, similar to the tube part 410. However, as long as the first semi-closed space of the tube part can be made negative pressure by operating the instrument 300 while connected to the instrument 300, the specific shape of the connecting part is not limited to the above, and may be configured in other cylindrical shapes such as a polygonal prism, similar to the tube part. The auxiliary tool 400 is not limited to a method of making the semi-closed space 413 negative pressure, and may be a method of pushing out the drug into 413 by operating the plunger of the medical device 200 to make the inside of 210 positive pressure without holding the instrument 300.
[0064] The materials constituting the treatment device kit 1 are not particularly limited. However, to give examples of materials, the inner tube 110, the outer tube 130, the tube portion 210, the tube portion 410, the pressing portion 220, the pressing member 320, the connecting member 240, the connecting member 340, etc. can be made of plastics such as polypropylene and polyethylene. The sealing member 230 and the sealing member 330 can be made of butyl rubber, silicone rubber, elastomer, etc. The injection needle 120 can be made of stainless steel, etc.
[0065] (Example of use) Next, a description will be given of an example of how to use the treatment device kit 1 according to this embodiment. First, a surgeon such as a doctor connects the connection member 240 of the medical device 200 to the connection portion 111 of the administration device 100, and connects the connection member 340 of the instrument 300 to the connection portion 440 of the auxiliary tool 400.
[0066] Next, with the injection needle 120 exposed to the outside from the tip 132 of the outer cylinder 130, the surgeon inserts the tip of the injection needle 120 of the administration device 100 into the notch 431 of the valve member 430 of the auxiliary tool 400, and places the tip of the injection needle 120 in the first semi-closed space 413 of the tube part 410. Next, the surgeon performs an operation to move the pressing member 320 in the axial direction so that the internal space of the tube part 310 of the instrument 300 expands. As a result, the first semi-closed space 413 of the auxiliary tool 400 becomes negative pressure.
[0067] As a result, at least a part of the anticancer drug contained in the internal space of the tubular part 210 of the medical device 200 moves from the internal space of the tubular part 210 to the lumen of the injection needle 120. With the tip of the injection needle 120 placed in the first semi-closed space 413 of the tubular part 410, the operator can visually confirm that the anticancer drug has come out of the tip of the injection needle 120 into the first semi-closed space 413 by performing an operation to move the anticancer drug placed in the tubular part 210 into the lumen of the injection needle 120 (priming).
[0068] Next, the surgeon removes the tip of the injection needle 120 from the first semi-closed space 413 of the tubular part 410, and stores the injection needle 120 in the tip 132 of the outer tube 130. If an anticancer drug adheres to the outer surface of the injection needle 120, the injection needle 120 is caused to pass through while being in contact with the valve member 430 when it leaves the first semi-closed space 413 of the tubular part 410. This allows the anticancer drug adhered to the outer surface of the injection needle 120 to be adhered to the valve member 430 and retained in the first semi-closed space 413 of the tubular part 410.
[0069] Next, the surgeon forms a small incision around the patient's abdomen. Then, under ultrasound, the surgeon punctures the injection needle 120 and the tip 132 of the outer tube 130 housing it percutaneously to access the tumor. Then, the surgeon punctures only the injection needle 120 into the tumor, and moves the pressing part 220 relatively to the tube part 210 in the axial direction so that the internal space of the tube part 210 is reduced, thereby administering the anticancer drug to the affected area (see FIG. 10). After the administration of the anticancer drug is completed, the surgeon houses the tip of the injection needle 120 in the tip 132 of the outer tube 130 (see FIG. 11), and removes the administration device 100 from the body. It should be noted that the treatment device kit 1 has been described above as including the instrument 300 and the auxiliary tool 400. However, as long as the anticancer drug described in this specification can exert a high antitumor effect, the treatment device kit that does not include the instrument 300 and the auxiliary tool 400 is also included in one embodiment of the present invention.
[0070] As described above, in this embodiment, the longitudinal dimension of the injection needle 120 of the administration device 100 is configured to be 50 mm or more. Therefore, the injection needle 120 can be inserted from the body surface to approach the tumor and administer the anticancer agent to the affected area. That is, in one aspect of the present invention, the administration device is provided with an injection needle of a length that can be inserted from outside the body to the tumor.
[0071] Moreover, the administration device 100 is configured such that the tip 132 of the outer tube 130 can store the tip of the injection needle 120. By configuring in this manner, it is possible to prevent the injection needle 120, which has touched the tumor after the anticancer drug is administered to the affected area, from touching the living body along the path from the affected area to the body surface. This makes it possible to prevent tumor seeding and leakage of the anticancer drug. That is, in one aspect of the present invention, the administration device further includes an outer tube that stores the injection needle.
[0072] Furthermore, administration device 100 is configured such that a sensor related to detection unit 140 is disposed in the liquid transfer path of injection needle 120, and detection unit 140 is electrically connected to notification unit 150 that notifies the pressure measured by detection unit 140. This allows administration device 100 to notify the user of the injection pressure during injection of the anticancer agent at the same time as administering the anticancer agent to the affected area. That is, in one aspect of the present invention, administration device measures and notifies the injection pressure at the same time as administering the anticancer agent.
[0073] One aspect of the present invention is a therapeutic device kit having an anticancer agent that induces immunogenic cell death and an administration device capable of administering the anticancer agent directly to tumor tissue, wherein the anticancer agent is administered using the administration device equipped with an injection needle long enough to puncture the tumor from outside the body.
[0074] One aspect of the present invention is a therapeutic device kit having an anticancer drug that induces immunogenic cell death and an administration device capable of administering the anticancer drug directly to tumor tissue, the administration device measuring and reporting the injection pressure at the same time as administering the anticancer drug.
[0075] One aspect of the present invention is a therapeutic device kit comprising an anticancer drug that induces immunogenic cell death and an administration device capable of administering the anticancer drug directly to tumor tissue, the administration device having a drug solution discharge hole at the tip or side of an injection needle.
[0076] One aspect of the present invention is a therapeutic device kit having an anti-cancer drug that induces immunogenic cell death and an administration device capable of administering the anti-cancer drug directly to tumor tissue, the administration device having a mechanism for safely loading the anti-cancer drug into an injection needle.
[0077] (Second embodiment of anticancer agent administration method) 14 to 16 are diagrams illustrating another embodiment of anticancer drug administration using the above-mentioned administration device 100. In addition to the first embodiment, the anticancer drug administration method can also be configured as follows.
[0078] In Fig. 14, the anticancer drug is administered to the affected area by puncturing the affected area using the above-mentioned treatment device kit 1 in combination with an endoscope. As shown in Fig. 14, the endoscope includes a video system main body 10 and a videoscope 20. Since a known endoscope can be used in this embodiment, the following description will focus on the part of the endoscope related to the injection needle 120 of the administration device 100.
[0079] The video system main body 10 performs processing for recording information captured by a videoscope 20 and displaying the information on a monitor (display).
[0080] The videoscope 20 includes an operation section 30 and an insertion section 40. The insertion section 40 includes a long member and is configured to have multiple lumens therein. As shown in FIG. 15, the insertion section 40 includes an imaging lumen 41, an irradiation lumen 42, a fluid flow lumen 43, and a treatment tool insertion lumen 44.
[0081] The imaging lumen 41 is provided as a lumen for installing a device for acquiring images of the inside of the body, such as a CCD camera. The irradiation lumen 42 is provided as a lumen for installing an illumination device, such as a light, so that the imaging location inside the body can be clearly imaged. The fluid flow lumen 43 is provided as a lumen for flowing fluids, such as water and air, as necessary. The treatment tool insertion lumen 44 is configured as a lumen for installing a treatment tool, such as forceps, which is inserted from the base end side and exposed from the tip side of the elongated member to perform various treatments.
[0082] In this embodiment, the treatment tool insertion lumen 44 can be inserted with an injection needle 120 of an administration device 100 constituting the treatment device kit 1 .
[0083] In administering an anticancer agent using an endoscope, the surgeon performs priming in the same manner as in the first embodiment, and then removes the tip of the injection needle 120 from the auxiliary tool 400. Then, the surgeon moves the tip of the insertion section 40 of the endoscope to the affected area using the operation section 30. After that, the surgeon inserts the injection needle 120 into the treatment tool insertion lumen 44, and administers the anticancer agent to the affected area from the tip of the injection needle 120 as shown in FIG.
[0084] This allows the condition of the affected area around the tumor to be confirmed by the endoscope, and an anticancer drug can be administered to the affected area by an injection needle 120 inserted through the treatment tool insertion lumen 44 of the endoscope as shown in FIG.
[0085] [Tumor tissue] Tumor tissues to which anticancer drugs are directly administered include cancer tissues. That is, the therapeutic device kit of this embodiment can be a therapeutic device kit for cancer treatment or prevention. The tumor is preferably a solid cancer, since the administration device can easily directly access the tumor and administer the anticancer drug. Solid cancers include hepatocellular carcinoma, colorectal cancer, rectal cancer, colon cancer, breast cancer, esophageal cancer, gastric cancer, bile duct cancer, pancreatic cancer, malignant melanoma, non-small cell lung cancer, small cell lung cancer, head and neck cancer (e.g., oral cancer, nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer, salivary gland cancer, and tongue cancer), renal cell cancer (e.g., clear cell renal cell carcinoma), ovarian cancer (e.g., serous ovarian cancer and ovarian clear cell adenocarcinoma), nasopharyngeal cancer, uterine cancer (e.g., cervical cancer and uterine body cancer), anal cancer (e.g., anal canal cancer), esophagogastric junction cancer, urothelial cancer (e.g., bladder cancer, upper urinary tract cancer, ureter cancer, renal pelvis cancer and urethra cancer), prostate cancer, fallopian tube cancer, primary peritoneal cancer, malignant pleural mesothelioma, gallbladder cancer, biliary tract cancer, skin cancer (e.g., uveal malignant melanoma and Merkel cell carcinoma), testicular cancer (germ cell tumor), vaginal cancer, vulvar cancer, penile cancer, small intestine cancer, endocrine system cancer, thyroid cancer, parathyroid cancer, adrenal cancer, spinal tumor, neuroblastoma, medulloblastoma, ocular retinoblastoma, neuroendocrine tumor, brain tumor (e.g., glioma (e.g., glioblastoma and gliosarcoma) and meningioma), and squamous cell carcinoma. In one embodiment, the tumor includes breast cancer, hepatocellular carcinoma, and colorectal cancer metastasized to the liver.
[0086] [Immune checkpoint inhibitors] In a preferred embodiment of the present invention, an anticancer agent is administered in combination with an immune checkpoint inhibitor, which provides a higher antitumor effect.
[0087] Immune checkpoint receptors exist on T cells and interact with ligands expressed on antigen-presenting cells. T cells recognize antigens presented on MHC molecules, become activated, and initiate an immune response, but T cell activation is regulated by immune checkpoint receptor-ligand interactions that occur in parallel. There are costimulatory and inhibitory immune checkpoint receptors, and T cell activation and immune responses are regulated by the balance between the two.
[0088] Cancer cells express ligands for inhibitory immune checkpoint receptors and use the receptors to evade destruction by cytotoxic T cells.
[0089] Immune checkpoint inhibitors inhibit the function of immune checkpoint receptors or ligands, and examples of such inhibitors include antagonists for inhibitory receptors and agonists for costimulatory immune checkpoint receptors.
[0090] The term "antagonist" includes various substances that block receptor activation through binding between the receptor and a ligand, such as substances that bind to the receptor and block the receptor-ligand binding, and substances that bind to the ligand and block the receptor-ligand binding.
[0091] Examples of antagonists against inhibitory immune checkpoints include antagonistic antibodies that bind to inhibitory immune checkpoint molecules (inhibitory receptors or ligands for such receptors), soluble polypeptides that do not activate receptors and are designed based on inhibitory immune checkpoint ligands, or vectors capable of expressing such polypeptides.
[0092] Specific examples of antagonists against inhibitory immune checkpoint receptors include anti-PD-1 antibodies, anti-CTLA-4 antibodies, anti-LAG-3 antibodies, anti-TIM-3 antibodies, and anti-BTLA antibodies.
[0093] Antagonists against ligands for inhibitory immune checkpoint receptors include anti-PD-L1 antibodies, anti-PD-L2 antibodies, anti-CD80 antibodies, anti-CD86 antibodies, anti-GAL9 antibodies, and anti-HVEM antibodies.
[0094] Among these, because of the high antitumor effect when used in combination with an anticancer drug, the immune checkpoint inhibitor is preferably at least one selected from the group consisting of anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, and anti-CTLA-4 antibody, more preferably an anti-PD-1 antibody and / or an anti-PD-L1 antibody, and even more preferably an anti-PD-1 antibody.
[0095] Antibodies such as anti-PD-1 antibodies, anti-PD-L1 antibodies, and anti-PD-L2 antibodies include monoclonal antibodies, polyclonal antibodies, single-chain antibodies, modified antibodies (e.g., "humanized antibodies" in which only the antigen recognition site is humanized), chimeric antibodies, bifunctional antibodies capable of simultaneously recognizing two epitopes, and antibody fragments (e.g., F(ab')2, Fab', Fab, or Fv fragments). The antibodies may be of any class, such as IgA, IgD, IgE, IgG, or IgM. From the viewpoint of specific binding to the antigen, it is more preferable to use monoclonal antibodies.
[0096] Monoclonal and polyclonal antibodies can be prepared by taking into consideration conventionally known methods.
[0097] The antibody used may be a commercially available product.
[0098] The method of administration of the immune checkpoint inhibitor may be the same as or different from that of the anticancer drug. The method of administration of the immune checkpoint inhibitor is not particularly limited, and includes oral administration, intravenous injection, intraarterial injection, subcutaneous injection, intradermal injection, intraperitoneal injection, intramuscular injection, intrathecal injection, percutaneous administration, percutaneous absorption, and other parenteral administration. Among them, the immune checkpoint inhibitor is preferably administered by intraperitoneal injection or intravenous injection, and more preferably by intravenous injection, which acts on the whole body, since it is expected to act not only in tumor tissue but also in lymph nodes associated with the tumor.
[0099] The order of administration of the anticancer agent and the immune checkpoint inhibitor is not particularly limited, and the anticancer agent and the immune checkpoint inhibitor may be administered simultaneously or at a time lag. In addition, when administering at a time lag, the immune checkpoint inhibitor may be administered after the anticancer agent, or the anticancer agent may be administered after the immune checkpoint inhibitor.
[0100] Immune checkpoint inhibitors act on immune checkpoint receptor-ligands on T cells to obtain their effects. It is believed that administering an immune checkpoint inhibitor after inducing T cells will enhance the antitumor effect, so it is preferable to administer the immune checkpoint inhibitor after administering an anticancer agent. For this reason, it is preferable to administer the anticancer agent before administering the immune checkpoint inhibitor. In the administration mode with a time lag, the administration routes may be the same or different, so long as they are administered with a time lag.
[0101] Examples of the formulation of the anticancer agent and the immune checkpoint inhibitor include a composition containing the anticancer agent and the immune checkpoint inhibitor (single formulation), and a combination of the anticancer agent and the immune checkpoint inhibitor separately formulated (drug kit). A suitable form is a combination of the anticancer agent and the immune checkpoint inhibitor separately formulated. That is, in this embodiment, it is preferable to use a therapeutic device kit that combines the anticancer agent, the administration device, and the immune checkpoint inhibitor. In addition, in the drug kit, the order of administration of the anticancer agent and the immune checkpoint inhibitor is not particularly limited, and the anticancer agent and the immune checkpoint inhibitor may be administered simultaneously or at a time lag. In addition, when administering at a time lag, the immune checkpoint inhibitor may be administered after the administration of the anticancer agent, or the anticancer agent may be administered after the administration of the immune checkpoint inhibitor. Since the antitumor effect is more enhanced, it is preferable to administer the anticancer agent and then the immune checkpoint inhibitor. By such an embodiment, a remarkable antitumor effect can be obtained. In the case of administration with a time lag, the administration routes may be the same or different, so long as the administration is with a time lag. In addition, the therapeutic device kit is preferably a therapeutic device kit for treating or preventing cancer.
[0102] The administration form when administering an anticancer drug and an immune checkpoint inhibitor in combination is not particularly limited as long as the administration route, administration frequency and dosage appropriate for each are adopted, and examples thereof include (1) administration as a composition containing an anticancer drug and an immune checkpoint inhibitor, i.e., administration as a single preparation, (2) simultaneous administration of two preparations obtained by separately formulating an anticancer drug and an immune checkpoint inhibitor via the same administration route, (3) administration of two preparations obtained by separately formulating an anticancer drug and an immune checkpoint inhibitor via the same administration route with a time lag, (4) simultaneous administration of two preparations obtained by separately formulating an anticancer drug and an immune checkpoint inhibitor via different administration routes, and (5) administration of two preparations obtained by separately formulating an anticancer drug and an immune checkpoint inhibitor via different administration routes with a time lag, etc. The drugs to be administered are not limited to these two drugs, and other drugs may be added.
[0103] A preferred administration form for the combined administration is a method in which an anticancer agent is administered followed by an immune checkpoint inhibitor.
[0104] Another aspect of the present invention is a method for treating or preventing a disease, comprising administering an effective amount of an anti-cancer drug that causes immunogenic cell death to a subject in need of treatment or prevention directly to tumor tissue using an administration device. Another aspect is a method for treating or preventing a disease, comprising administering an effective amount of an anti-cancer drug that causes immunogenic cell death to a subject in need of treatment or prevention directly to tumor tissue using an administration device, and administering an effective amount of an immune checkpoint inhibitor. In particular, it is preferable that the disease is cancer.
[0105] The subject is preferably a mammal, and more preferably a human.
[0106] In addition, when the anticancer drug and the immune checkpoint inhibitor are administered with a time lag, it is necessary to administer the drugs at an interval sufficient to enhance the antitumor effect. The specific administration interval is appropriately determined for each individual case, taking into consideration the symptoms, age, sex, etc. of the patient.
[0107] In addition, the anticancer agent and the immune checkpoint inhibitor may be administered in a certain cycle. It is preferable to appropriately adjust the administration cycle so as to be suitable for the combined use. The specific administration frequency, dosage, infusion administration time, administration cycle, etc. are appropriately determined according to each individual case, taking into consideration the symptoms, age, sex, etc. of the patient.
[0108] Administration of immune checkpoint inhibitors alone is conventionally known, and is administered, for example, in the range of 2 to 3 mg / kg / day, once to several times a day.
[0109] When an anticancer drug and an immune checkpoint inhibitor are used in combination, the dosage can be set to the same as when the drug is administered alone or a lower dosage (for example, 0.10 to 0.99 times the maximum dosage when the drug is administered alone), depending on the usual route of administration.
[0110] The weight ratio (mg / kg / day) of the dosage of the immune checkpoint inhibitor and the anticancer drug will also be determined appropriately for each individual case, taking into account the patient's symptoms, age, sex, etc. EXAMPLES
[0111] The effects of the present invention will be described using the following examples and comparative examples. In the examples, the terms "parts" and "%" may be used, but unless otherwise specified, they are "parts by weight" or "% by weight". Furthermore, unless otherwise specified, each operation is carried out at room temperature (25°C).
[0112] [1. Drug efficacy evaluation in mice] A: Material 1. Test substance The test substances and solvents described in Table 1 below were used.
[0113] [Table 1]
[0114] <Preparation of test substance administration solution> ·Anti-mouse PD-1 antibody (αPD-1) administration solution preparation (100μg / 200μL / head) 0.88 mL of αPD-1 (7.24 mg / mL) solution was added to 11.8 mL of PBS and mixed to make the concentration 0.5 mg / mL. Preparation of Doxorubicin (hereinafter simply referred to as Dox) administration solution Dox 10 mg / mL solution: 1.0 mL of physiological saline was injected into a vial of Adriamycin Injection 10 (containing 10 mg (potency) of Japanese Pharmacopoeia doxorubicin hydrochloride per vial) to dissolve the powder.
[0115] <Preparation of intratumoral administration solution> Assuming that the body weight of all cases was 20 g, the above-mentioned 10 mg / mL solution was diluted stepwise to the following concentrations. ·1mg / kg(0.020mg / 20μL / site, Dox1.0mg / mL) 0.5 mL of 10 mg / mL Dox solution was added to 4.5 mL of physiological saline and mixed. ·0.3mg / kg(0.006mg / 20μL / site,Dox0.3mg / mL) 1.5 mL of 1.0 mg / mL Dox solution was added to 3.5 mL of physiological saline and mixed. ·0.1mg / kg(0.002mg / 20μL / site, Dox0.1mg / mL) 1.0 mL of 0.3 mg / mL Dox solution was added to 2.0 mL of physiological saline and mixed.
[0116] Preparation of intravenous solutions The above 10 mg / mL solution was serially diluted to the following concentrations: ·1mg / kg(1mg / 5mL / kg, Dox0.2mg / mL) 0.3 mL of 10 mg / mL Dox solution was added to 14.7 mL of physiological saline and mixed. ·0.3mg / kg(0.3mg / 5mL / kg,Dox0.06mg / mL) 3 mL of 0.2 mg / mL Dox solution was added to 7 mL of physiological saline and mixed.
[0117] 2.Animals used We used 216 female BALB / cAnNCrlCrlj mice (6 weeks old at time of introduction, Charles River Laboratories Japan, Ltd.). Microbial control SPF mice were used.
[0118] 3. Drugs and reagents used The serum required for cell culture was FBS (Gibco, Cat No. 26140-079, inactivated at 56℃ for 30 min). RPMI-1640 (model number: A10491-01), 0.25% Trypsin-EDTA (model number: 25200-056), Penicillin-Streptomycin (model number: 15140-122), and PBS (model number: 14190-144) were purchased from Thermo Fisher Scientific, and isoflurane inhalation anesthetic solution was purchased from Mylan Pharmaceuticals Co., Ltd.
[0119] B. Experimental Method 1. Group composition Cancer cells were transplanted into 216 mice. The day of transplantation was Day 0, and from Day 8 onwards, the following groups (130 mice in total) were used. PBS or αPD-1 was administered intraperitoneally (ip), and saline or Dox was administered intravenously (iv) or intratumorally (it). Administration was performed three times in total on Days 8, 11 and 14.
[0120]
number
[0121] 2.Cell culture Frozen cells (CT26.WT, ATCC, CRL-2638) were thawed in a warm bath at approximately 37°C and placed in culture medium (RPMI-1640 supplemented with 10% FBS and Penicillin-Streptomycin) that had been warmed to 37°C. The cells were then centrifuged (1000 rpm, 3 min, room temperature) using a KUBOTA tabletop refrigerated centrifuge 2810 (SN Sharp J90124-A000). The supernatant was discarded, culture medium was added, and the cells were suspended well by pipetting. The cells were transferred to a culture flask and cultured under environmental conditions of 37°C and 5% CO2 concentration. Subculture was performed when the cells reached 70-90% confluency. The culture medium was removed from the culture flask, washed with PBS, and the cells were detached with 0.25% Trypsin-EDTA solution. Culture medium was added, the supernatant was discarded by centrifugation, and the cells were appropriately diluted with culture medium and cultured. The cells were adjusted to reach the required cell number and subcultured, and after the required cell number was reached, they were used for transplantation.
[0122] 3. Cancer cell transplantation The cultured cells were detached with 0.25% trypsin-EDTA. They were then centrifuged (1000 rpm, 3 min, 4°C) using the above-mentioned centrifuge, and the supernatant was removed and resuspended in PBS. The number of live cells in the suspension was calculated using the trypan blue dye exclusion method. Based on this value, the cells were diluted with refrigerated PBS to obtain the final cell suspension (1 × 10 7 The final cell suspension was stored on ice until immediately before transplantation. The CT26.WT cell suspension (5 × 10 5 cells / 50 μL / head) was transplanted subcutaneously into the right dorsal region using a 1 mL tuberculin syringe (Terumo syringe, SS-01T) equipped with a 23G×1″ needle (Terumo needle, NN-2325R).
[0123] 4. Grouping The day of transplantation was Day 0, and the tumor volume on Day 8 was approximately 41 mm 3 From about 145 mm 3Animals were selected and divided into groups according to the group composition described in "B.1." so that the average tumor volume of each group was uniform. When dividing the animals into groups, animals with tumor volumes that were too small or too large, tumors that were divided into two, or tumors with a flat shape were excluded from the group.
[0124] 5. Tumor Size Measurement The short and long diameters of the tumors were measured every two days from Day 8 (the day of grouping) to Day 26 (18 days after the start of drug administration), and the tumor volume was calculated using the following formula.
[0125] Tumor volume (mm 3 )=1 / 2×L×W×W L: tumor long axis (mm), W: tumor short axis (mm).
[0126] 6. Administration of Test Substance PBS or αPD-1 was administered intraperitoneally at 200 μL / head, and the residual solution was discarded. For intraperitoneal administration, a 1 mL tuberculin syringe (Terumo syringe, SS-01T) equipped with a 26G×1 / 2'' needle (Terumo needle, NN-2613S) was used. Saline or Dox was administered into the tail vein or intratumorally. For intravenous administration, 5 mL / kg was administered based on the most recent body weight, and for intratumor administration, 20 μL / site was administered assuming a body weight of 20 g. For intravenous administration, a needle-embedded syringe (27G×1 / 2'', FN syringe, SS-010F2713) was used, and for intratumor administration, a needle-embedded syringe (29G×1 / 2'', FN syringe, SS-010F2913) was used. Administration of either vehicle or test substance was performed three times in total on days 8, 11, and 14. In groups 5, 7, 9, 11, and 13, administration of αPD-1 was performed at least one hour after administration of Dox.
[0127] 7. Observation of general condition and tumor surface condition The general condition was observed once a day from the day of animal introduction until the day of the final tumor diameter measurement, and the condition of the tumor surface was observed once a day from the day after transplantation (Day 1) until the day of the final tumor diameter measurement (Day 26).
[0128] 8. Data Analysis Graphing and statistical analysis were performed using the statistical analysis software GraphPad Prism 8 (Version 8.3.0, GraphPad Software, LLC) and Microsoft Office Excel 2016.
[0129] The tumor volume results for each group were taken as the value on Day 20. No. 3 in Group 1 "Saline iv + PBS ip" and No. 4 in Group 13 "αPD-1 100 μg / head ip" were excluded because they reached the humane endpoint on Day 17. The mean and standard error (Mean ± Standard error) for each group are shown. The results are shown in Table 2 below and Figure 1.
[0130] [Table 2]
[0131] In addition, in the following groups, significance tests were performed using unpaired t tests (vs *; P<0.05, **; P<0.01, ***; P<0.001) to verify the combined effect of αPD-1 (ip) on Day 20 and to verify differences in efficacy depending on the route of Dox administration.
[0132] The results were as follows:
[0133] [Table 3]
[0134] In addition, assuming that the humane endpoint (the point at which the tumor volume exceeded 10% of the body weight) was death, survival curves were plotted for groups 1, 4, 5, 6, 11, 12, and 13 using the aforementioned GraphPad Prism 8. The results are shown in Figure 2.
[0135] From the above results, it can be understood that the group in which doxorubicin was administered directly to the tumor tissue had a high antitumor effect. It can also be seen that an even higher antitumor effect can be obtained by combining doxorubicin with an immune checkpoint inhibitor. In particular, the combined administration of 1 mg / kg doxorubicin and an immune checkpoint inhibitor had a particularly high antitumor effect, and the administration of an immune checkpoint inhibitor at a dose that does not show an antitumor effect alone showed an enhanced antitumor effect compared to the intratumoral administration of an anticancer drug alone, resulting in a synergistic effect between the anticancer drug and the immune checkpoint inhibitor. In immunotherapy, the combined use of drugs with different mechanisms of action does not necessarily result in an enhanced antitumor effect. Considering these circumstances, the synergistic effect of the combination is a surprising result.
[0136] [2. PK study in rats] A. Experimental Method 1.Animals used Animal species: rat, lineage: Crl:CD(SD), sex: female, age: 5 weeks, microbial control: SPF 2. Reagents Used
[0137] [Table 4]
[0138] [Table 5]
[0139] 5. Group composition The group consisted of two groups: an intratumoral administration group and an intravenous administration group.
[0140] 6. Cell preparation for transplantation 13762-MAT-BIII (ATCC CRL-1666, lot. 70003533) stock cells were removed from the liquid nitrogen tank and thawed in a 37°C warm bath. Immediately after thawing, the cells were transferred to a tube containing 10 mL of DMEM medium. The supernatant was removed using a KUBOTA tabletop refrigerated centrifuge 5500 (1000 rpm, 5 minutes, room temperature) and the cells were resuspended in 5 mL of DMEM medium. The cell suspension was added to a T75 flask containing 10 mL of DMEM medium and placed in a CO2 incubator (37°C, 5% CO2, same below).
[0141] After 3 days, the cells were collected together with the medium from the T75 flask into a 50 mL tube, and the remaining cells were collected into a 50 mL tube using approximately 10 mL of DMEM medium. After centrifugation using the above-mentioned centrifuge (1000 rpm, 5 min, room temperature), the supernatant was removed. The cells were resuspended in 10 mL of DMEM medium and counted using a hemocytometer, resulting in approximately 2.3 × 10 6 A cell suspension of 10 cells / mL was obtained. 1 mL of cells was added to a T75 flask containing 10 mL of DMEM medium and placed in a CO2 incubator. The next day, the cells were collected from the T75 flask together with the medium. 2 mL of the total volume of approximately 35 mL was taken and transferred to a T75 flask containing 10 mL of DMEM medium.
[0142] After 4 days, the cells were collected together with the medium from one T75 flask. Approximately 5 mL of DMEM medium was then added to the T75 flask to collect the remaining cells (twice). After centrifugation (1000 rpm, 5 min, room temperature) using the aforementioned centrifuge, the supernatant was removed, and 10 mL of DMEM medium was added and resuspended to obtain approximately 3.7 × 10 6 Approximately 1 mL of the cell suspension was added to each of two T75 flasks (containing 10 mL of DMEM medium) and placed in a CO2 incubator.
[0143] After 3 days, the cells were collected together with the medium from two T75 flasks. Approximately 5 mL of DMEM medium was then added to each T75 flask to collect the remaining cells (twice). After centrifugation (1000 rpm, 5 min, room temperature) using the aforementioned centrifuge, the supernatant was removed, and 20 mL of DMEM medium was added and resuspended to obtain approximately 3.3 × 10 6Approximately 0.6 mL of the cell suspension was added to 15 T75 flasks (containing 10 mL of DMEM medium) and placed in a CO2 incubator.
[0144] After 3 days, cells were collected together with the medium from 15 T75 flasks. Approximately 5 mL of DMEM medium was then added to each T75 flask to collect the remaining cells (twice). After centrifugation (1000 rpm, 5 min, room temperature) using the aforementioned centrifuge, the supernatant was removed, and 10 mL of DMEM medium was added and resuspended to obtain approximately 3.1 × 10 7 A cell suspension with a cell concentration of 4 × 10 cells / mL was obtained. 8 mL of this cell suspension was centrifuged using the above-mentioned centrifuge (1000 rpm, 5 minutes, room temperature), the supernatant was removed, and 6 mL of PBS was added to resuspend the cells in the suspension at approximately 4 × 10 cells / mL. 7 A cell suspension of 100 cells / mL was obtained.
[0145] 8. Cell transplantation The flank skin was pinched and 13762-MAT-BIII cells were inoculated into one area per mouse, approximately 4 × 10 cells per area. 6 cells / 100μL were subcutaneously transplanted.
[0146] 9. Tumor size measurement and grouping On the 4th, 7th, and 9th days after cell transplantation, under the same anesthesia as at the time of cell transplantation, the tumor size formed in the flank was measured once for each individual using a vernier caliper in terms of the long and short diameters. The tumor size was calculated as long diameter x (short diameter). 2 The tumor size was calculated by the formula: ÷ 2. Based on the tumor size on the 9th day, 2 mice were selected for the intravenous administration group and 3 mice for the intratumoral administration group in descending order of tumor size.
[0147] 10. Drug Administration Drug preparation: 1 mL of saline was added to each of two vials of Adriamycin Injection 10, and dissolved to prepare approximately 2 mL of a 10 mg / mL doxorubicin hydrochloride solution. 1.6 mL of the 10 mg / mL doxorubicin hydrochloride solution was taken and 6.4 mL of saline was added to prepare a 2 mg / mL doxorubicin hydrochloride solution. Assuming a body weight of 200 g, 0.2 mg of doxorubicin hydrochloride (0.1 mL of drug solution) was administered to all individuals to give a dosage of 1 mg / kg.
[0148] Drug administration: The administration was performed under the same anesthesia as during cell transplantation.
[0149] <Intratumoral injection> (1) A syringe filled with doxorubicin hydrochloride (2 mg / mL) was set on a syringe pump (TE-361, Terumo Corporation) and an extension tube was connected. A three-way stopcock was connected to the distal end, and a manometer and an extension tube were connected. (2) The injection needle for administration was connected to the distal end of the extension tube. The line was filled with the drug solution before administration. (3) An ultrasound probe was placed around the tumor to confirm its location, and then an injection needle (22G) was inserted to confirm that the tip was near the center of the tumor. (4) While monitoring the pressure inside the administration line, the drug solution was administered for 1 minute at 0.1 mL / min using a syringe pump. The pressure inside the line was monitored while the needle was still inserted for 30 minutes after the start of administration. The needle was removed 30 minutes after the start of administration. (5) Blood samples were taken from the jugular vein at 0.5 mL each time using a 1 mL syringe containing 1 μL of heparin sodium (final concentration of heparin sodium: 5 units / mL) before drug administration and 5, 15, 30, and 60 minutes after the start of drug administration. (6) 60 minutes after blood collection, the abdominal aorta was immediately cut open and the animals were euthanized. (7) The tumor was removed and weighed. The collected blood was centrifuged (1800g, 10 minutes, 4°C) to extract approximately 0.2 mL of plasma. The tumor tissue and plasma were frozen and stored in an ultra-low temperature freezer until shipment.
[0150] <Intravenous administration> (1) A syringe filled with doxorubicin hydrochloride (2 mg / mL) was set on a syringe pump and a 27 G butterfly needle was connected. (2) The line was filled with the drug solution before administration. (3) A butterfly needle was inserted into the tail vein and the drug solution was administered at 0.1 mL / min for 1 minute using a syringe pump.
[0151] Plasma collection, euthanasia, and sample processing were performed in the same manner as for intratumoral administration (5), (6), and (7).
[0152] 11. Doxorubicin hydrochloride concentration measurement <Reagents> The standard substance used was Doxorubicin hydrochloride (product number: D1515, Sigma-Aldrich Corp.), and the internal standard substance was Daunorubicin hydrochloride (product number: 30450, Sigma-Aldrich Corp.).
[0153] <Preparation of standard solution> The standard stock solution was prepared by accurately weighing 1.07 mg of doxorubicin hydrochloride (1.00 mg as doxorubicin, correction factor: 1.07) and dissolving it in methanol to make it 100 μg / mL, and the internal standard stock solution was prepared by accurately weighing 1.0 mg of daunorubicin hydrochloride and dissolving it in methanol to make it 100 μg / mL. The standard stock solution was appropriately diluted with methanol to prepare the standard solution at 10.0 to 10,000 ng / mL when used. The internal standard solution was appropriately diluted with methanol to prepare the internal standard solution at 200 ng / mL when used.
[0154] <Pretreatment> Plasma doxorubicin concentration measurement The measurement sample was melted at room temperature, stirred, and then centrifuged (2000×g, 4℃, 5 minutes), and 20μL of the supernatant was collected in a micro test tube and used for the experiment. Proteins were removed with methanol, and after centrifugation, the supernatant was transferred to a glass test tube and concentrated to dryness under a nitrogen stream. The residue was redissolved by adding 0.1% formic acid-acetonitrile (70:30, v / v) to prepare the measurement sample.
[0155] Measurement of tissue doxorubicin concentration The rat tissue was disrupted by adding 5 times the total weight of methanol to prepare a homogenate. When used, the tissue homogenate was centrifuged (2000×g, 4℃, 5 minutes), and 20μL of the supernatant was collected in a micro test tube for pretreatment. Proteins were removed with methanol, and after centrifugation, the supernatant was transferred to a glass test tube and concentrated to dryness under a nitrogen stream. The residue was redissolved by adding 0.1% formic acid-acetonitrile (70:30, v / v) to prepare the measurement sample.
[0156] measurement The LC-MS / MS equipment used was a UPLC system (Waters) and a triple quadrupole mass spectrometer API5000 (Sciex). The data processing software used was Analyst ver. 1.5.1. The LC-MS / MS measurements were performed under the following conditions.
[0157] Lower limit of quantification Plasma: 10.0 ng / mL (below the lower limit of quantification is "<10.0") Tissue: 60.0 ng / g (below the lower limit of quantification is "<60.0")
[0158] [Table 6]
[0159] [Table 7]
[0160] 8. Data Processing Microsoft Office Excel 2016 was used for data processing.
[0161] 9.Results
[0162] [Table 8]
[0163] [Table 9]
[0164] These results indicate that direct administration into the tumor using the device results in high intratumoral doxorubicin concentrations, but low plasma doxorubicin concentrations. This suggests that direct administration into the tumor using the device can have a high antitumor effect while reducing systemic side effects.
[0165] [3. Evaluation of CTL activation using flow cytometry (mouse)] A. Material 1. Cell and animal experiments <cell> ·CT26.WT(ATCC):Cat. CRL-2638, Lot. 70016788 / ATCC <Animal> BALB / cAnNCrlCrlj mouse, female, 6 weeks old, 90 mice: Charles River Japan Co., Ltd. (used for 7 weeks). Microbial control SPF mice were used.
[0166] <Reagents>
[0167] [Table 10]
[0168] [Table 11]
[0169] B. Experimental Method 1. Cell and animal experiments 1.1.Cell culture RPMI supplemented with 10% FBS and 1% Penicillin-Streptomycin was prepared as the medium (hereafter referred to as the medium). Frozen CT26.WT cells (Passage 2) were thawed at 37°C, added to the medium that had been brought to room temperature, and mixed. Then, the cells were centrifuged (1,000 rpm, 5 min, room temperature) using a floor-type refrigerated centrifuge (S700FR, Kubota Manufacturing Co., Ltd.) and the supernatant was discarded. The medium was added and the cells were suspended well by pipetting. The cells were transferred to a culture flask and cultured under environmental conditions of 37°C and 5% CO2 concentration. Passage was performed 3 days (Passage 3), 5 days (Passage 4), and 7 days (Passage 5) after the start of cell culture. The subculture medium was removed from the culture flask, washed, and the cells were detached with trypsin, medium was added to stop the activity of trypsin, and the cells were diluted with the appropriate medium to disperse and proliferate. The cells were counted using the trypan blue exclusion method and Countess II, and appropriately diluted based on the viable cell count obtained as a result of the measurement.
[0170] 1.2. Cell transplantation The subcultured cells (Passage 5) were centrifuged (1,000 rpm, 5 min, room temperature) using the centrifuge described above, the supernatant was removed, and the cells were resuspended in medium. The number of live cells in the suspension was calculated using the same method as for cell counting during subculture. Based on this value, the cell suspension was separated and centrifuged (1,000 rpm, 5 min, room temperature) using the centrifuge described above, and then replaced with PBS. The cells were diluted with 5 × 10 6 A cell suspension was prepared to a cell concentration of 10 cells / mL. Ninety animals were anesthetized with isoflurane (induction anesthesia: 2.0-3.0%, maintenance anesthesia: 2.0%), and the hair at the transplantation site (lower right abdomen) was shaved. The prepared CT26.WT cells were subcutaneously transplanted (5 × 10 cells / mL) into the right flank (between the forelimb and hindlimb) using a 29G FN syringe. 5 The day of transplantation was defined as Day 0.
[0171] 1.3.Tumor size measurement On the day of grouping (Day 8), the short and long diameters of the tumor were measured, and the tumor volume was calculated using the following formula.
[0172] Tumor volume (mm 3 ) = 1 / 2 × L × W × W L: Long diameter of tumor (mm), W: Short diameter of tumor (mm) 1.4. Grouping Grouping was performed based on the tumor volume on Day 8. At this time, excluding individuals with "irregularly shaped tumors", 42 animals with the smallest tumor volume were excluded. Among the 90 tumor-bearing animals, 48 were grouped so that the average values of the tumor volumes were uniform according to the following group compositions.
[0173]
Table 12
[0174] 1.5. Preparation of test substance administration solution <Preparation of Dox administration solution> Dox 10 mg / mL: 1.0 mL of Saline was injected into a 10 vial of Adriamycin for injection to dissolve the powder, and it was used as a stock solution.
[0175] <i.t. (intratumoral administration) administration solution> Based on the average body weights (21 g) of Groups 2 and 3 at the time of grouping, the above-mentioned 10 g / mL stock solution was diluted 9.5-fold according to Table 13 below to obtain an i.t. administration solution of Dox 1 mg / kg.
[0176]
Table 13
[0177] <i.v. (intravenous administration) administration solution> According to Table 14 below, the above-mentioned 10 mg / mL stock solution was diluted 100-fold to obtain an i.v. administration solution of Dox 1 mg / kg.
[0178]
Table 14
[0179] <αPD-1 antibody (Anti-mouse PD-1 antibody) administration solution preparation> 0.50 mL of the αPD-1 stock solution (7.24 mg / mL) was added to 6.74 mL of PBS and mixed to give 100 μg / 200 μL / head, creating the αPD-1 antibody administration solution (0.5 mg / mL).
[0180] Administration On Day 8, the day of grouping, according to the group composition described above, groups 1, 2, 3, and 6 were anesthetized under isoflurane anesthesia (induction anesthesia: 2.0-3.0%, maintenance anesthesia: 2.0%) and administered saline or Dox into the tumor (it) at 20μL / head using a 29G FN syringe. Groups 4 and 5 were awake and administered Dox into the tail vein (iv) using a 27G needle and a 1mL Terumo syringe, with the dose calculated at 10mL / kg based on the body weight of each individual.
[0181] After administration of saline and Dox, PBS or αPD-1 antibody was intraperitoneally administered at 200 μL / head using a Top double-step needle and a 1 mL Thermosyringe while the mice were awake.
[0182] 1.7. Sampling of lymph nodes near the tumor On Day 11, three days after drug administration, the mice were euthanized by exsanguination under isoflurane anesthesia (induction anesthesia: 2.0-3.0%, maintenance anesthesia: 2.0%), and samples were taken from two locations, the inguinal lymph nodes and the axillary lymph nodes near the subcutaneous tumor.
[0183] 2. Flow Cytometry 2.1. Cell isolation from lymph nodes The collected lymph nodes were placed in a tube containing 500 μL of RPMI1640 + 10% FBS medium and mashed using a BioMasher II. The mashed lymph nodes were passed through a nylon mesh and collected in a 25 mL tube. The tube in the BioMasher II was washed again with 1 mL of RPMI1640 + 10% FBS medium, passed through a nylon mesh, and collected in a 25 mL tube. The collected tube was centrifuged at 400 × g, 4 ° C, and 5 min, the supernatant was decanted, and the cells were loosened by tapping. For samples containing blood, 1 mL of hemolytic agent (ACK Lysing Buffer) was added, the samples were suspended, and the samples were left to stand at room temperature for 1 to 2 min (this operation was not performed for samples without blood). 9 mL of RPMI1640 + 10% FBS was added, and the samples were centrifuged at 400 × g, 4 ° C, and 5 min, the supernatant was decanted, and the cells were loosened by tapping. After confirming that there was no residual hemolysis, 15 mL of PBE buffer (rinsing solution:BSA solution = 20:1) was added and mixed. After centrifugation at 400 × g, 4℃, and 5 min, the supernatant was decanted, the cells were loosened by tapping, and 2 mL of stain buffer was added. This sample was passed through a cell strainer and collected in a 25 mL tube. 30 μL of the collected cell solution was dispensed into a 1.5 mL tube, mixed with trypan blue in a 1:1 ratio, and the number of cells was counted using Countess II. Based on the counted number of cells, 3.0 × 10 cells were placed in a 5 mL round tube. 6 The cell suspension was dispensed (total volume 3.0 × 10 6 (If the amount was less than 100 cells, the entire amount was used.)
[0184] 2.2. Lymph node isolated cell staining (dead cell staining, blocking, tetramer staining, antibody staining) <Dead cell staining> 1 mL of PEB buffer was added to the round tube containing the cells and mixed. After centrifugation at 400×g, 4℃, 5 min, the supernatant was decanted, the cells were gently loosened by vortexing, and 1 mL of PBS was added. After centrifugation at 400×g, 4℃, 5 min, the supernatant was decanted, the cells were gently loosened by vortexing, 100 μL of diluted dead cell staining solution (100-fold diluted Zombie Aqua) was added, mixed gently by vortexing, and left to stand at room temperature, protected from light, for 20 min. After leaving to stand, 2 mL of PEB buffer was added, and centrifuged at 400×g, 4℃, 5 min, the supernatant was decanted, and the cells were gently loosened by vortexing.
[0185] <Blocking> After staining for dead cells and washing, 25 μL of blocking solution (3-fold diluted Clear Back) was added to each round tube, which was then gently vortexed to mix. After mixing, the tubes were left to stand at 4°C in the dark for 5 minutes.
[0186] <Tetramer staining> A cocktail for staining AH-1 tetramer (APC-AH-1 tetramer per tube; 5 μL, Stain Buffer; 20 μL) was prepared and 25 μL was added to the round tube after the blocking reaction. For the Isotype Control (All) and Isotype Control (AH-1 tetramer, CD69), a cocktail for staining isotype tetramer (APC-β-galactosidase tetramer per tube; 5 μL, Stain Buffer; 20 μL) was prepared and 25 μL was added to the round tube after the blocking reaction. After adding the tetramer, the tube was vortexed lightly and left at 4℃, protected from light, for 40 min.
[0187] <Antibody staining> An antibody staining cocktail (PerCP-CD45 antibody; 2.5 μL, PE-Cy7-CD3 antibody; 2.5 μL, APC-Cy7-CD4 antibody; 2.5 μL, FITC-CD8 antibody; 10 μL, PE-CD69 antibody; 2.5 μL, Stain Buffer; 5 μL per tube) was prepared and 25 μL was added to the round tube after tetramer staining. In addition, isotype tetramer staining cocktail (PerCP-isotype antibody; 2.5 μL, PE-Cy7-isotype antibody; 2.5 μL, APC-Cy7-isotype antibody; 2.5 μL, FITC-isotype antibody; 10 μL, PE-isotype antibody; 2.5 μL, Stain Buffer; 5 μL per tube) was added to the isotype control (All), and isotype tetramer staining cocktail (PerCP-CD45 antibody; 2.5 μL, PE-Cy7-CD3 antibody; 2.5 μL, APC-Cy7-CD4 antibody; 2.5 μL, FITC-CD8 antibody; 10 μL, PE-isotype antibody; 2.5 μL, Stain Buffer; 5 μL per tube) was added to the isotype control (AH-1 tetramer, CD69). After adding the antibody staining cocktail, the mixture was gently vortexed and then allowed to stand at 4°C in the dark for 20 minutes.
[0188] After antibody staining, 2 mL of PEB buffer was added to the round tube, and the tube was centrifuged at 400×g, 4℃, and 5 min. The supernatant was decanted, and the cells were gently loosened by vortexing. This washing procedure was repeated twice. 100 μL of 4% paraformaldehyde solution was added to each of the washed round tubes, and the tubes were left standing at 4℃, in the dark, for 15 min. After the reaction, 2 mL of PEB buffer was added, the tubes were centrifuged at 400×g, 4℃, and 5 min. The supernatant was decanted, and the cells were gently loosened by vortexing. 1 mL of Stain buffer was added thereto, and the tubes were centrifuged at 400×g, 4℃, and 5 min. The supernatant was decanted, and the cells were gently loosened by vortexing, and 350 μL of Stain buffer was added. This sample was passed through a 5 mL tube with a cell strainer (35 μm) to prepare the measurement sample. The tubes were left standing at 4℃ and used for measurement the next day.
[0189] 2.3. Measurement using flow cytometry Measurements were performed using a flow cytometer, CytoFLEX S (Beckman Coulter). The number of cells that uptake the antibody was 200,000 living cells (2 × 10 5 The cells were collected as samples and as many were as possible. Measurements and analysis were performed using CytoFLEX S equipped with CytoExpart software Version 2.4 (Beckman Coulter, Inc.).
[0190] Gating was performed as follows (Figure 3). (1) An FSC-A / SSC-A plot was developed from All Events and a cell population was selected. (2) A Zombie Aqua / FSC-A plot was developed from the cell population, and living cells were selected after removing the dead cell population (Zombie Aqua positive cells). (3) CD45 / SSC-A was expanded from living cells and the CD45+ population was selected. (4) CD3 / SSC-A was expanded from the CD45+ population, and the CD3+ population was selected. (5) FSC-H / FSC-A was expanded from the CD3+ cell population, doublets were removed, and the single cell 1 population was selected. (6) The single cell 1 population was expanded using SSC-H / SSC-A, doublets were removed, and the single cell 2 population was selected. (7) CD8 / CD4 were expanded from the single cell 2 population, and CD8+ cells were used as total CTL and CD4+ cells as helper T cells. (8) Total. CTLs were expanded with CD8 / CD69, and CD69+ cells were selected as CD69+ CTLs (activated CTLs). (9) Total. CTLs were expanded with CD8 / AH-1 Tetramer, and AH-1 Tetramer+ cells were selected as AH-1 specific CTLs (cancer antigen-specific CTLs).
[0191] Because the numbers of CD69+ cells and AH-1 specific CTLs were small, the boundaries between the negative and positive regions were determined based on the data from the isotype control (AH-1 tetramer, CD69).
[0192] 2.4. Calculation of cell numbers in each cell population The percentage (%) of each of the gated cell groups listed below was calculated for each individual using the following formula. Total CTL(%):CD45 + CD3 + CD8 + Cell number (#) / CD45 + CD3 + Number of cells x 100 CD69+CTL(%):CD45 + CD3 + CD8 + CD69 + Cell number (#) / CD45 + CD3 + CD8 + Number of cells x 100 AH-1 specific CTL (%): CD45 + CD3 + CD8 + AH-1 tetramer + Cell number (#) / CD45 + CD3 + CD8 + Number of cells x 100 In addition, the number of cells of each cell group in the tissue was calculated using the following formula, using the cell concentration (cells / mL) calculated using CountessII after cell isolation in 2.1 and the cell number (#) of the cell group calculated from the proportion (%) of each cell group in the flow cytometry measurement. Total number of cells in tissue (#) = cell concentration (cells / mL) × total volume of stain buffer containing cells (mL) * Number of viable cells (#) = total number of cells (#) x viable cell rate (%) / 100 CD45 + Number of cells (#) = Number of viable cells (#) × CD45 + Cell rate (%) / 100 CD3+ Number of cells (before doublet removal) (#) = CD45 + Number of cells (#) x CD3 + Cell rate (%) / 100 CD3 + Number of cells (FSC doublets removed) (#) = CD3 + Cell count (before doublet removal) x CD3 + Cell (FSC doublets removed) rate (%) / 100 T cell count (#) = CD3 + Number of cells (FSC doublets removed) x CD3 + Cell (SSC doublet removal) rate (%) / 100 Total CTL count (#) = T cell count (#) × CD8 + Cell rate (%) / 100 CD69 + CTL count (#) = Total CTL count (#) × CD69 + Cell rate (%) / 100 AH-1 specific CTL count (#) = Total CTL count (#) × AH-1 tetramer + Cell rate (%) / 100 * The "volume of stain buffer containing cells (mL)" was calculated as the amount of stain buffer added through a cell strainer after centrifugation and decanting the supernatant before cell counting (lymph nodes: 2 mL).
[0193] 2.4. Graphing and statistical analysis The cell counts of each group were graphed using the analysis software GraphPad Prism (Prism8), and the mean and standard error (Mean ± Standard error) of the cell counts of each group were shown. To verify whether activation of antitumor immunity was observed in each cell group compared to the vehicle group, the vehicle group was used as the control group, and the rate of increase in cell counts was calculated in all groups. The results are shown in Table 15.
[0194] 2.5.Results The average values and standard errors for the cell counts of each cell group are shown in Figures 4 to 6. Figure 4 shows the total CTL count, Figure 5 shows the AH-1 specific CTL count, and Figure 6 shows the CD69+ CTL count. Here, the total CTL count refers to the total number of CTLs, the AH-1 specific CTL count refers to CTLs that specifically recognize tumors, and the CD69+ CTL count refers to CTLs in an activated state.
[0195] The increase rates of total CTLs, AH-1 specific CTLs, and CD69+ CTLs in each group relative to the control are shown in Table 15 below.
[0196] [Table 15-1]
[0197] [Table 15-2]
[0198] [Table 15-3]
[0199] It is understood that in a system in which doxorubicin is administered directly to tumor tissue, stronger antitumor immunity is induced than in the case of intravenous administration. Furthermore, it is understood that the induction of antitumor immunity is enhanced when immune checkpoint inhibitors are used in combination. Since no combination effect is observed in the case of intravenous administration, such combination effect is not necessarily predictable. It is presumed that the enhancement of antitumor immunity induction by the combination of immune checkpoint inhibitors contributes to the synergistic effect of the antitumor effect described above.
[0200] In this embodiment, the administration device may be any of the administration devices described in the administration device section. [Explanation of symbols]
[0201] 1 treatment device kit, 100 dosing devices, 120, 120a injection needle, 130 outer cylinder, 140 detection unit, 150 Notification Department.
Claims
1. Anticancer drugs that induce immunogenic cell death and and an administration device capable of administering the anticancer agent directly to tumor tissue, A therapeutic device kit that induces activation of anti-tumor immunity by administering the anti-cancer drug using the administration device.
2. The therapeutic device kit of claim 1 , wherein the anticancer drug is administered in combination with an immune checkpoint inhibitor.
3. The therapeutic device kit of claim 2, wherein the immune checkpoint inhibitor is at least one selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, and an anti-CTLA-4 antibody.
4. The therapeutic device kit according to any one of claims 1 to 3, wherein the tumor is a solid cancer.
5. The therapeutic device kit according to any one of claims 1 to 4, wherein the anticancer drug is at least one selected from the group consisting of doxorubicin, epirubicin, oxaliplatin, paclitaxel, and pharma- ceutically acceptable salts thereof.
6. The treatment device kit according to any one of claims 1 to 5, wherein the administration device is provided with an injection needle having a length capable of piercing a tumor from outside the body.
7. The therapeutic device kit of claim 6 , wherein the administration device comprises a barrel that houses the injection needle.
8. The treatment device kit according to any one of claims 1 to 7, wherein the administration device measures and reports an injection pressure while administering the anticancer drug.
9. The device kit according to any one of claims 1 to 8, wherein the administration device has a drug solution discharge hole at the tip or side of an injection needle.
10. The device kit according to any one of claims 1 to 9, wherein the administration device is provided with a mechanism for safely loading an anticancer drug into the injection needle.
Citation Information
Patent Citations
Use of mhc class ii ligands as adjuvants for vaccines and use of lag-3 in cancer therapy
JP2001510806A
Combination therapy of immunotoxins and checkpoint inhibitors
JP2018533626A
